Cara Therapeutics Employees 2024

Cara Therapeutics Aktienanalyse

What does Cara Therapeutics do?

Cara Therapeutics Inc. is a US pharmaceutical company based in Stamford, Connecticut, specializing in the development of novel therapies for the treatment of pain conditions. The company was founded in 2004 by Derek Chalmers and Eric Carter and has been publicly traded on the NASDAQ since its IPO in 2014. Cara Therapeutics Inc.'s history is closely linked to the discovery of adenosine A2A receptor modulation. In recent years, the company has successfully utilized this class of compounds in innovative ways to develop novel pain treatment solutions. The company also has a close collaboration with Yale University and other leading research institutions in the field of neurology and pain research. Cara Therapeutics Inc.'s business model is based on the development and commercialization of new pain therapies, particularly based on Cara - a synthetic adenosine A2A receptor antagonist. The medications developed by Cara Therapeutics Inc. are designed to provide effective pain relief to patients without the strong side effects of traditional pain medications such as opioids. Cara Therapeutics Inc. is divided into several divisions that encompass different areas of the company. These include research and development, production, sales and marketing, as well as the supply chain. The research and development division of Cara Therapeutics Inc. works closely with leading research institutions and scientists to continuously develop new treatment options. The focus is always on the needs of patients and healthcare providers, with an emphasis on advancing treatment options with Cara and other new compounds. The production facilities of Cara Therapeutics Inc. are specialized in the production of Cara-based therapies and aim to ensure high quality and patient access. The company works closely with various partners domestically and internationally to ensure global patient access. The sales and marketing division of Cara Therapeutics Inc. is focused on placing the company's products on the market and communicating the benefits of the offered therapies to patients. The company relies on a global network of distribution partners and close collaboration with healthcare professionals. An important focus of the company is the supply chain - ensuring continuous patient access to necessary medications as well as ensuring compatibility and traceability of treatment options. Some of the most well-known and important products of Cara Therapeutics Inc. include Korsuva, a pain medication developed for the treatment of pruritus in patients with chronic kidney disease on hemodialysis, as well as a wide range of other pain therapies. Overall, Cara Therapeutics Inc. is an innovative company specializing in the treatment of pain conditions and is at the forefront of pain therapy research and development. The company places special emphasis on ensuring that their pain therapies are as effective and safe as possible in order to provide patients with effective pain relief. Cara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Cara Therapeutics's Employee Base

Cara Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Cara Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Cara Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Cara Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Cara Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Cara Therapeutics Stock

How many employees does Cara Therapeutics have this year?

Cara Therapeutics has 80 undefined employees this year.

How many employees did Cara Therapeutics have compared to the previous year?

Compared to the previous year, Cara Therapeutics had 0% more employees.

What impact did the number of employees have on the company Cara Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of Cara Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Cara Therapeutics?

The number of employees can also have an impact on investors of Cara Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Cara Therapeutics affect the company?

An increase in equity of Cara Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Cara Therapeutics's equity affect the company?

A reduction in equity of Cara Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Cara Therapeutics?

Some factors that can influence the equity of Cara Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Cara Therapeutics so important for investors?

The equity of Cara Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Cara Therapeutics influence the company?

The number of employees at Cara Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Cara Therapeutics evolved in recent years?

In recent years, the number of employees at Cara Therapeutics has changed by 0.

How many employees does Cara Therapeutics currently have?

Cara Therapeutics currently has 80 undefined employees.

Why is the number of employees important for investors of Cara Therapeutics?

The number of employees is important for investors of Cara Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Cara Therapeutics take to change the number of employees?

To change the number of employees, Cara Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Cara Therapeutics pay?

Over the past 12 months, Cara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cara Therapeutics?

The current dividend yield of Cara Therapeutics is .

When does Cara Therapeutics pay dividends?

Cara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cara Therapeutics?

Cara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cara Therapeutics located?

Cara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cara Therapeutics from 6/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did Cara Therapeutics pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of Cara Therapeutics in the year 2023?

In the year 2023, Cara Therapeutics distributed 0 USD as dividends.

In which currency does Cara Therapeutics pay out the dividend?

The dividends of Cara Therapeutics are distributed in USD.